Depocyt is a drug owned by Pacira Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 03, 2015. Details of Depocyt's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5723147 | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
Mar, 2015
(9 years ago) |
Expired
|
| US5455044 | Method for treating neurological disorders |
May, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Depocyt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Depocyt's family patents as well as insights into ongoing legal events on those patents.
Depocyt's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Depocyt's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 03, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Depocyt Generic API suppliers:
Cytarabine is the generic name for the brand Depocyt. 9 different companies have already filed for the generic of Depocyt, with Meitheal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Depocyt's generic
Alternative Brands for Depocyt
Depocyt which is used for treating lymphomatous meningitis via intrathecal administration., has several other brand drugs using the same active ingredient (Cytarabine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Celator Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Cytarabine, Depocyt's active ingredient. Check the complete list of approved generic manufacturers for Depocyt
About Depocyt
Depocyt is a drug owned by Pacira Pharmaceuticals Inc. It is used for treating lymphomatous meningitis via intrathecal administration. Depocyt uses Cytarabine as an active ingredient. Depocyt was launched by Pacira Pharms Inc in 1999.
Approval Date:
Depocyt was approved by FDA for market use on 01 April, 1999.
Active Ingredient:
Depocyt uses Cytarabine as the active ingredient. Check out other Drugs and Companies using Cytarabine ingredient
Treatment:
Depocyt is used for treating lymphomatous meningitis via intrathecal administration.
Dosage:
Depocyt is available in injectable, liposomal form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG/ML | INJECTABLE, LIPOSOMAL | Discontinued | INJECTION |